BCL2 and breast carcinoma: Vorinostat and entinostat induce the cyclin-dependent kinase inhibitor p21 to alter expression of proapoptic proteins of the Bcl-2 family21, 22, and have therapeutic potential for many types of malignancies including colon cancer, glioma, lung cancer, breast cancer, and hepatocellular carcinoma as a single treatment or in combination with other drugs23–26.